How to compare results after surgery or radiation for localized prostate carcinoma : Prostate specific antigen (PSA) outcome (No), posttreatment PSA doubling time (Maybe), or survival (Yes)?
✍ Scribed by Anthony V. D'Amico
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 43 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
In addressing the clinically relevant question regarding prostate specific antigen (PSA) outcome data in the study presented by Vicini and colleagues in this issue of Cancer, the author concurs with Vicini et al. that only a randomized trial powered to assess survival ultimately can answer the important question of the relative efficacy of surgery versus various forms of radiation therapy in the management of patients with localized prostate carcinoma. In addition, the author points out that one posttreatment clinical parameter, the posttreatment PSA doubling time, has emerged from both the surgical literature and the radiation literature as a potential candidate for predicting the likelihood of death from prostate carcinoma after primary treatment failure.
See also pages 2126–35.